These are trying times, especially for health care practitioners. Together, as managed care pharmacy professionals, we face challenges to patient care. AMCP CEO Susan A. Cantrell, RPh, CAE addresses these unique challenges in her latest blog post.
As representatives of the drug supply and payment chain, ranging from pharmaceutical manufacturers, pharmacies, specialty pharmacies, managed care pharmacy, pharmacy benefit managers (PBMs), to health plans, we are aligned on the important principle that the private sector and state and federal governments must work together to facilitate Americans’ reliable access to needed prescription drugs during the COVID-19 pandemic.
AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.
Aligning stakeholder perspectives, providing timely and meaningful drug pricing information, and establishing common definitions of health care value could help ensure patients are able to access medications they need at costs they can afford.
Partnership Forum: Participants considered the possible solutions for addressing rising costs and discussed challenges, practical steps for implementing point of sale rebates and other proposed solutions, and discussed how patient assistance programs and copay policies fit into the affordability equation. This forum will develop recommendations and possible solutions to improve price transparency, address the rising costs of medications, and help patient understand and manage drug cost.
Our organizations are pleased to submit these comments regarding the Food and Drug Administration’s (“FDA”) proposed rule regarding wholesale importation of prescription drugs from Canada. Collectively, we represent over 200,000 pharmacists, student pharmacists, residents and pharmacy technicians in all settings.